Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,932 recruiting studies in this area right now.
By phase
- Not applicable2,031
- Phase 21,075
- Phase 1791
- Phase 1/Phase 2481
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma179
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Lymphedema49
- Acute Myeloid Leukemia (AML)48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center62
- City of Hope Medical Center58
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California397
- Texas185
- Alabama157
- Maryland152
- Arizona127
- Massachusetts105
- Florida104
- New York96
- Ohio72
- Minnesota69
Recruiting studies4,932 total
- NCT05355051RecruitingPhase 2
Azacitidine plus pembrolizumab for Hodgkin lymphoma after relapse
This Phase 2 study tests azacitidine together with pembrolizumab in people whose Hodgkin lymphoma has come back or did not respond (relapsed/refractory). It aims to see whether this combination can control cancer and improve outcomes, especially when standard high-dose chemotherapy is not an option.
Houston, TexasAges 1 year+ - NCT05336201RecruitingPhase 2
Brain training program for teens with sickle cell disease
This Phase 2 study tests a cognitive (thinking) training program to help teens with sickle cell disease prepare for the changes in their care as they grow older. It may help with skills like learning, attention, and planning for transition to adult care.
Birmingham, AlabamaAges 10–18 - NCT05317403RecruitingPhase 1
Venetoclax plus chemo to change cancer cell behavior
This Phase 1 trial tests whether venetoclax, combined with chemotherapy and a “cancer cell behavior” medicine strategy, can improve treatment for people with AML that has come back or not gone into remission. It’s mainly looking at safety and early signs of benefit.
Milwaukee, WisconsinAges 1–25 - NCT05357781Recruiting
Test immunoglobulin treatment for fatigue in multiple sclerosis
This trial studies whether giving immunoglobulins (antibody medicines) can improve fatigue in people with multiple sclerosis (MS). It will enroll only people whose MS and fatigue are stable and meet specific blood/health criteria.
Bern, Canton of BernAges 18–65 - NCT05340465RecruitingPhase 2
IV iron in preterm babies to reduce blood transfusions
This Phase 2 study tests whether giving a specific IV iron (darbe plus IV iron) can help preterm babies need fewer blood transfusions while still keeping their iron levels in a safe range. It focuses on babies in the NICU who were born early, and it compares transfusion use and iron sufficiency over time.
Seattle, WashingtonAges Up to 3 days - NCT05361694Recruiting
Study aims to distinguish stable vs worsening early myeloma
This study looks at two different “precursor” conditions that can happen before multiple myeloma: MGUS and smoldering myeloma (SMM). Researchers want to better tell which cases are more likely to progress, using blood/urine tests and sometimes bone marrow tissue.
Miami, FloridaAges 18 years+ - NCT05342584RecruitingPhase 1
Venetoclax plus intensive chemo for AML and advanced MDS
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
The Bronx, New YorkAges 18–75 - NCT05360160RecruitingPhase 1/Phase 2
Oral menin inhibitor plus AML medicines for new or relapsed AML
This trial tests an all-pill (oral) combination treatment—menin inhibitor SNDX-5613 plus decitabine/cedazuridine (ASTX727) and venetoclax—for acute myeloid leukemia (AML). It’s designed for people who are newly diagnosed and can’t get the strongest chemotherapy, or for certain other AML groups who may still benefit.
Houston, TexasAges 12 years+ - NCT05312658Enrolling by invitation
Aortic compression during C-section to reduce blood loss
This trial studies whether gently compressing the major blood vessel in the abdomen during a C-section can reduce blood loss. It may help you stay safer during surgery, especially by lowering the chance of heavy bleeding.
StockholmAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75 - NCT05313243RecruitingPhase 2
Pembrolizumab plus brentuximab for relapsed T-cell lymphoma
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
New Haven, ConnecticutAges 18 years+ - NCT05322850RecruitingPhase 1/Phase 2
Engineered donor stem cell transplant for childhood blood cancers
This trial tests a new way to prepare donor stem cells before a transplant for children and young adults with blood cancers. The goal is to make the transplant safer and more effective, potentially reducing complications like graft-versus-host disease.
Gainesville, FloridaAges Up to 50 years - NCT05359991Recruiting
Exercise study in children and teens with lung or blood conditions
This study tests how safe and effective a structured exercise program is for children and teens. It also compares results between children with sickle cell disease, cystic fibrosis, and healthy peers (and some teens after COVID-19 infection).
Irvine, CaliforniaAges 10–17 - NCT05344833RecruitingPhase 2
Isatuximab and lenalidomide after transplant for myeloma
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
Chicago, IllinoisAges 18 years+ - NCT05323409Recruiting
Better overall care for certain cancer patients
This study looks at how to improve day-to-day support and coordination between cancer doctors and primary care doctors for people with certain early cancers. It may help if you have other ongoing health problems (like diabetes or high blood pressure) or lifestyle factors that need ongoing management during cancer treatment.
Houston, TexasAges 18 years+ - NCT05336812RecruitingPhase 2
Acalabrutinib with venetoclax or obinutuzumab for untreated CLL
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
Columbus, OhioAges 18 years+ - NCT05357794RecruitingPhase 2
Skin-directed radiation plus brentuximab for lymphoma skin disease
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
Houston, TexasAges 18 years+ - NCT05089227RecruitingPhase 2
Long-term apixaban to prevent clots in autoimmune hemolytic anemia
This Phase 2 trial tests whether taking long-term apixaban (a blood thinner) can prevent venous blood clots in people with autoimmune hemolytic anemia (AIHA). It may help reduce the risk of dangerous clotting events if you meet safety and risk criteria.
DijonAges 18 years+ - NCT05272384RecruitingPhase 1
Testing nivolumab plus ASTX727 for hard-to-treat lymphoma
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
Birmingham, AlabamaAges 18 years+ - NCT05289687RecruitingPhase 2
Daratumumab for hard-to-clear T-cell leukemia traces
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
Chicago, IllinoisAges 18 years+ - NCT05270096Recruiting
Matches children and young people to leukemia treatment plans
This trial is set up to review tumor lab test results to help doctors choose the most appropriate next treatment for people with leukemia that has returned or did not respond. It mainly matters for younger patients who are not already on a standard treatment path.
GhentAges birth–25 years - NCT05283993Recruiting
Hospital study following people with plasma cell disorders
This is a hospital-based study that follows people with plasma cell disorders to better understand these conditions. It mainly gathers information from patients who are confirmed to have one of several related diseases.
BeijingAges Any age - NCT05272826RecruitingPhase 2
New, untreated myeloma study using four medicines
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
Edmonton, AlbertaAges 65 years+ - NCT05270200RecruitingPhase 1/Phase 2
Azacitidine and chidamide after transplant to prevent AML relapse
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
Guanzhou, GuandongAges 18–60
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,932 recruiting hematology studies from the U.S. registry right now, out of 7,407 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.